We next stratified the population of 361 pMMR CRC patients in the NCBI-GEO dataset into PNPLA2high and PNPLA2low subgroups (Supplementary Fig. 7b), and evaluated the association of PNPLA2 with the benefit from FU-based adjuvant chemotherapy. This evidence concerns the gene PNPLA2 and colorectal carcinoma.